top of page

ImmunOs Therapeutics AG raises CHF 71M in Series B financing

ImmunOs co-founder and CSO Osiris Belaunzaran with the team

We are pleased to announce the Series B financing round of our portfolio company ImmunOs Therapeutics AG. ImmunOs is a leading developer of the next generation immuno-oncology assets targeting the innate immune system. The CHF 71m Series B round was co-led by experienced US and EU biotech investors Samsara Biocapital, Lightspeed Venture Partners and Gimv, with the participation of Redalpine alongside other new and existing investors. 

The financing will be used to advance ImmunOs  lead agent, IOS-1002, through phase 2 clinical trials and advance additional oncology and autoimmune disease programs of the company’s HLA-based pipeline. IOS-1002 is a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen (HLA) that targets key components of the innate immune system, including LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1, and synergizes with the adaptive immune system, thereby leading to profound anti-tumor activity. A Phase 1 clinical trial is planned to start in the second half of 2022. Additionally, ImmunOs has established a U.S. subsidiary to further expand its international reach, execute future U.S. clinical trials, and strengthen its transatlantic operations and team.

“We are delighted to close this significant financing round led by a group of top-tier U.S. and European investors. The raise underlines our promising, first-in-class immunotherapy approach for the treatment of both solid and liquid tumors. The funding allows us to advance our lead program, IOS-1002, into clinical trials, expand our pipeline in oncology and autoimmune disease, and strengthen our transatlantic operations. We are honored that renowned investors such as Samsara, Lightspeed, Gimv, Mission BioCapital, GL Capital, PEAK6, and Fiscus have joined our investor base.” said Sean R. Smith, CEO of ImmunOs Therapeutics AG.

In conjunction with the financing, ImmunOs Therapeutics has expanded its Board of Directors to include three new members: Shelley Chu, MD, PhD, Partner at Lightspeed, Marcos Milla, PhD, Venture Partner at Samsara, and Andreas Jurgeit, PhD, Partner at Gimv, will join the Company’s Board of Directors, which currently includes Reinhard Ambros, PhD, Chairperson and former Head of the Novartis Venture Fund, Daniel Vasella, MD, Vice Chairperson and former Chairperson and CEO of Novartis AG, Markus Hosang, PhD, General Partner at BioMed Partners, Michael Baran, PhD, Partner at Pfizer Ventures, and Sean R. Smith, CEO of ImmunOs.

Redalpine congratulates the entire ImmunOs team on this closing and looks forward to taking the next steps together. 

For more information, please visit ImmunOs’ website and here.


bottom of page